Lacosamide
Lacosamide. Selective slow-inactivation enhancer of voltage-gated Na+ channels — distinct from the fast-inactivation drugs (carbamazepine… Oral half-life 13 h.
Selective slow-inactivation enhancer of voltage-gated Na+ channels — distinct from the fast-inactivation drugs (carbamazepine, lamotrigine, phenytoin). Used for partial-onset seizures. Cardiac PR prolongation at high doses.
PK: half-life corrected 13 -> 12.5 h. The cited paper (PMID:23148731) reports "12.5 and 12.4 h in plasma, and 13.1 and 13.3 h in saliva" — the stored value was a rounding of the SALIVA figure. The IV row was filed under a paper with no intravenous arm; it now cites Cawello 2012 (PMID:22722651), which establishes IV/oral bioequivalence and so justifies carrying the same half-life. F 1 is supported: "Oral bioavailability is high (100 %) for a dose up to 800 mg" (PMID:25957198). V 42 L and ka 1.4 /h dropped — no PubMed abstract states a lacosamide volume, 42 L is the approval document 0.6 L/kg x 70, and the 1.4 traces to a bioequivalence RATIO of 1.48, not a rate.
Pharmacokinetics
- Oral — t½ 12.5 h · F 100%
- IV — t½ 12.5 h · F 100%
Sources: PMID:23148731, PMID:22722651, PMID:25957198